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940Objectives: Aged hearts are particularly vulnerable to ischemia-reperfusion injury. Our objective was to
determine if del Nido cardioplegia, which contains lidocaine, less blood, and less calcium than our standard
cardioplegia, provides superior protection for aged hearts. We also sought to determine if the lidocaine in del
Nido cardioplegia is adequate to prevent Naþ influx via the window current.
Methods: Sodium channel kinetics were measured in rat cardiomyocytes with and without lidocaine. Recovery
after 60minutes of cardioplegic arrestwas assessed in isolatedworking senescent rat hearts.DelNido cardioplegia
was delivered as a single dose (n¼ 8) because it is used clinically, and standard cardioplegia was delivered as an
induction dose with re-dosing every 20 minutes (n¼ 8). After 20 minutes of reperfusion, hearts were switched to
working mode for 60 minutes. Flows were indexed to ventricular dry weight. Troponin release was assayed.
Results: Sodium channel kinetics indicated that the lidocaine concentration in del Nido cardioplegia minimizes
the potential for Naþ influx via the window current. Spontaneous contractions occurred in fewer hearts arrested
with del Nido cardioplegia (88% vs 13%; P ¼ .01), and troponin release was reduced (0.24 vs 0.89 ng/mL;
P ¼ .017). Cardiac output was approximately 90% of baseline in the del Nido group compared with
approximately 50% in the standard group (173  14 vs 86  22 mL $ min1 $ g1; P ¼ .0008). Stroke
work was higher in the del Nido group (93  6 vs 41  10 mL $ mm Hg $ g1; P ¼ .0002).
Conclusions: Del Nido cardioplegia prevents spontaneous contractions during arrest, reduces troponin release,
and results in superior myocardial function in isolated aged hearts. Del Nido cardioplegia has the potential to
provide superior myocardial protection for older patients undergoing cardiac surgery. (J Thorac Cardiovasc
Surg 2013;146:940-8)The growing number of elderly patients requiring cardiac
surgery is an important group at higher risk for cardiac
dysfunction and death postoperatively.1,2 Aged hearts are
particularly susceptible to reperfusion injury after the
ischemic periods that occur during cardiac surgery3-5
owing to changes in the way cardiomyocytes deal with
intracellular Ca2þ, particularly during ischemia.5-8
Del Nido cardioplegia is used in several centers for
myocardial protection during pediatric cardiac surgery.9-11
Compared with the standard 4:1 blood cardioplegia we
use in our adult practice, del Nido cardioplegia is more
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The Journal of Thoracic and Cardiovascular SurgCa2þ, and contains lidocaine (Table 1). Del Nido cardiople-
gia usually is given as a single dose,9-11 whereas our
standard cardioplegia is given as an induction dose
followed by maintenance doses approximately every
20 minutes. The del Nido cardioplegia strategy results in
lower postoperative troponin release in pediatric patients
compared with our standard cardioplegia.9
Because elderly myocardium is similar to immature
myocardium in that both are particularly susceptible to
reperfusion injury related to Ca2þ overload,3-8,12-14 we
hypothesized that a del Nido cardioplegia strategy also
may be beneficial in the elderly. We previously showed,
in cardiomyocytes from aged rats (z24 mo), that arrest
with del Nido cardioplegia results in less activity during
the ischemic period, lower diastolic Ca2þ during ischemia
and reperfusion, and avoidance of Ca2þ-induced
hypercontraction during early reperfusion.15 The objective
of this study was to determine if the beneficial effects
seen with del Nido cardioplegia in aged cardiomyocytes
translate into improved functional recovery in elderly whole
hearts.
Sodium influx is thought to be the main cause of
intracellular Ca2þ accumulation during ischemia by
driving reverse-mode Naþ/Ca2þ exchange.16,17 During
hyperkalemic cardioplegic arrest, membrane depolarization
opens a proportion of the voltage-gated Naþ channelsery c October 2013
Abbreviation and Acronym
INa ¼ sodium current
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inactivated rapidly, thereby preventing action potential
generation and propagation, but a small fraction remain
tonically available and allow Naþ to flow into the cell via a
window current.18-20 Lidocaine used as an additive to
depolarizing cardioplegia may limit Naþ influx by
blocking the window current, however, this has not been
well described. We investigated whether the concentration
of lidocaine present in del Nido cardioplegia is adequate to
minimize the potential forNaþ influxvia thewindowcurrent.
MATERIALS AND METHODS
Experimental Animals and Anesthesia
Experiments were performed in accordance with guidelines published
by the Canadian Council on Animal Care.21 Male Fisher 344 rats
(3-4 mo for isolated cardiomyocyte studies, and 23-24mo for isolated heart
studies) obtained from Charles River Laboratories (Saint-Constant,
Canada) were heparinized (intraperitoneally, 3000 U/kg; Pharmaceutical
Partners of Canada, Richmond, Ontario, Canada), and anesthetized with
sodium pentobarbital (intraperitoneally, 160 mg/kg; VeterinaryMedication
Distribution Centre; Saint-Hyacinthe, Quebec, Canada). Hearts were
removed rapidly and placed in ice-cold Tyrode’s solution for isolated
cardiomyocyte studies (NaCl 140 mmol/L, KCl 5.4 mmol/L, Na2HPO4 1
mmol/L, CaCl2 1 mmol/L, MgCl2 1 mmol/L, glucose 10 mmol/L, HEPES
5 mmol/L, pH 7.4), or Krebs-Henseleit buffer for isolated heart studies
(NaCl 118 mmol/L, KCl 4.71 mmol/L, NaHCO3 25.0 mmol/L, KH2PO4
1.20 mmol/L, CaCl2 2.50 mmol/L, MgSO4 1.20 mmol/L, glucose 11
mmol/L, ethylenediaminetetraacetic acid 0.5 mmol/L, equilibrated with
95% O2/5% CO2, pH 7.4).
Cardiac Myocyte Isolation
Ventricular cardiomyocytes were obtained by enzymatic dissociation.
Hearts cannulated via the aorta were perfused with Tyrode’s solution
(37C, 5 min), followed by 10 minutes with Ca2þ free Tyrode’s, then
Tyrode’s containing collagenase type II (73.7 U/mL; Worthington
Biochemical Corp, Lakewood, NJ), taurine (20 mmol/L), CaCl2 (30
mmol/L), and bovine serum albumin (0.1%). The right ventricle was
dissected off and manually triturated to separate individual cardiomyo-
cytes, which were stored in Kraft-Br€uhe solution (K-glutamate 100
mmol/L, K-aspartate 10 mmol/L, KCl 2.5 mmol/L, KH2PO4 10 mmol/L,
MgSO4 2 mmol/L, glucose 20 mmol/L, taurine 20 mmol/L, creatine 5
mmol/L, ethylene glycol tetraacetic acid 0.5 mmol/L, HEPES 5 mmol/L,
bovine serum albumin 0.1%, pH 7.2). Only quiescent rod-shapedmyocytes
with clear striations were selected for these studies.
Electrophysiological Solutions and Protocols
The sodium current (INa) was recorded in single cardiomyocytes using
the whole-cell patch-clamp technique with reduced extracellular Naþ
concentrations to facilitate voltage clamping. Myocytes were superfused
with modified Tyrode’s (NaCl 12 mmol/L, CsCl 130 mmol/L, TEA-Cl
5.4 mmol/L, CaCl2 1 mmol/L, MgCl2 1 mmol/L, HEPES 10 mmol/L,
glucose 5 mmol/L, pH 7.4, 22C-23C) including NiCl2 (40 mmol/L) and
nitrendipine (10 mmol/L) to block Ca2þ currents. The pipette solution
contained CsCl 135 mmol/L, CaCl2 0.1 mmol/L, MgCl2 1 mmol/L,
NaCl 5 mmol/L, ethylene glycol tetraacetic acid 10 mmol/L,The Journal of Thoracic and CaMg-adenosine triphosphate 4 mmol/L, Na-phosphocreatine 6.6 mmol/L,
Na-guanosine triphosphate 0.3 mmol/L, and HEPES 10 mmol/L, pH 7.2.
The resistance of the borosilicate glass micropipettes (1.5 mm outer
diameter, 0.75 mm inner diameter) was 3 to 5 MU, seal resistance was 2
to 15 GU, and rupturing the sarcolemma in the patch for voltage clamp
experiments resulted in access resistances of 5 to 15 MU. Series resistance
compensation averaged 80% to 85% using an Axopatch 200B amplifier
(Molecular Devices, Sunnyvale, Calif). Data were digitized using a
Digidata 1440 and pCLAMP 10 software (Molecular Devices).
The voltage clamp protocol for measuring INa current-voltage relation-
ships and activation kinetics consisted of holding myocytes at -100 mVand
then giving a series of 20-ms, 10-mV steps from 80 to þ60 mv. INa
activation kinetics were determined by calculating chord conductance
(G) using the following equation: G ¼ I/(VmErev), where Vm represents
the depolarizing voltages and Erev is the reversal potential estimated
from the current-voltage relation of INa. The protocol for measuring INa
inactivation consisted of holding myocytes at140 mVand giving a series
of 500-ms voltage-clamp conditioning steps from 120 mV to 20 mV
followed by a 20-ms voltage clamp test step to 20 mV. Activation and
inactivation curves were generated by fitting normalized data with a
Boltzmann function to determine the V1/2 of activation (V1/2[act]), and
inactivation (V1/2[inact]) in the presence and absence (control) of lidocaine
0.36 mmol/L, as found in del Nido cardioplegia.
Isolated Working Heart
Hearts were cannulated via the aorta and pulmonary vein on a working
heart apparatus (Radnoti, Inc, Monrovia, Calif), and perfused retrograde
with Krebs-Henseleit buffer at 10 mL/min (37C). A temperature probe
and electrocardiogram electrode were placed through the pulmonary artery
into the right ventricular outflow tract. Left atrial and aortic pressure and
aortic flow (Transonic Systems, Inc, Ithaca, NY) were monitored
continually using a PowerLab data acquisition system (ADI Instruments,
Colorado Springs, Colo). Coronary flow was measured by timed collection
of effluent. After a 5-minute stabilization period, hearts were switched to
constant pressure mode (100 cm H2O) for 5 minutes, and then into working
heart mode for 5 minutes (preload, 20 cm H2O; afterload, 100 cm H2O).
Only hearts that met the following predetermined baseline criteria were
used in this study: heart rate greater than 200 bpm, regular rhythm, cardiac
output greater than 25 mL/min, and coronary flow greater than 10 mL/
min.22 After the baseline working heart period, hearts were arrested with
cardioplegia as described later, and then exposed to ambient room
temperature (22C23C) for a 60-minute ischemic period. Reperfusion
began with retrograde perfusion at 4 mL/min and increased in
0.5-mL/min increments every 30 seconds to 10 mL/min. Coronary effluent
then was collected and frozen (80C) for later determination of troponin
concentration (2010-2-HS, rat serum cardiac troponin-I enzyme-linked
immunosorbent assay; Life Diagnostics, Inc). After a total of 15 minutes,
hearts were switched to constant pressure mode for an additional 5 minutes
and then into working heart mode for 60 minutes. At the end of the
protocol, the ventricles were blotted dry, weighed, then desiccated at
80C for 24 hours and re-weighed. All flow values were indexed to dry
weight of the ventricles.
Cardioplegia Preparation and Delivery
Autologous blood was collected from the chest cavity using a syringe
containing heparin (200 U) as the hearts were being harvested.
Cardioplegia solutions were prepared according to our clinical protocols
(Table 1), cooled in an ice bath, and oxygenated. Before delivery, the
cardioplegia was filtered using a 20-mm pore size vacuum filter
(EMD Millipore, Billerica, Md). The cardioplegia temperature was
1.9C  0.4C.
The cardioplegia strategies used in this study were modeled after those
we use in the clinic.9 Standard cardioplegia was delivered as an induction
dose (15 mL/kg) followed by additional doses (5 mL/kg) every 20 minutesrdiovascular Surgery c Volume 146, Number 4 941
TABLE 1. Composition of cardioplegia solutions
Standard
cardioplegia
del Nido
cardioplegia
Base solution (1 L) D5 0.225% NaCl Plasmalyte A (ref)
Components (mmol/L)
Na 38.8 140
Cl 38.8 98
K 5
Mg 1.5
Acetate 27
Gluconate 23
Glucose 278
Additives (mL/L base solution)
KCl 2 mEq/mL 44 13
NaHCO3 1 mEq/mL 100 13
MgSO4 0.2 g/mL 15 10
Lidocaine 1% — 13
Mannitol 25% — 13
Dilution (blood:cardioplegia) 4:1 1:4
Estimated final composition
(mmol/L)
K 18 24
Mg 5 7
Ca 1.0 0.24
Glucose 51 1
Lidocaine — 0.36
Estimated final osmolarity
(mOsm/L)
0.396 0.375
Estimated final hematocrit (%) z25 z6
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induction dose (15 mL/kg) with no additional doses during the
60-minute ischemic period. The cardioplegia was delivered by hand
injection at pressures of 50 mm Hg or less.
Statistical Analysis
Data are presented as mean  SEM. Tests for statistical significance
included the following: paired t test, unpaired t test, the Fisher exact test,
and mixed linear model analysis followed by the Tukey-Kramer test where
appropriate.RESULTS
The Lidocaine Concentration Used in del Nido
Cardioplegia Minimizes the Potential for Naþ
Window Current During Cardioplegic Arrest
To determine if the lidocaine concentration in del Nido
cardioplegia is adequate to minimize the potential for
Naþ influx via the window current, Naþ channel
activation and inactivation curves were examined in the
presence and absence of lidocaine 0.36 mmol/L
(Figure 1). Lidocaine shifted the inactivation curve to the
left (V1/2[inact] 101.2  0.7 vs 88.9  0.3 mV;
P ¼ .00019; n ¼ 8), with no change in slope factor,
indicating lower Naþ channel availability at any given
membrane potential. Furthermore, the activation curve
was shifted to the right (V1/2[act] 47.7  0.7 vs 56.7 942 The Journal of Thoracic and Cardiovascular Surg0.4 mV; P < .001; n ¼ 8), indicating that opening of
available channels is reduced with lidocaine at any given
membrane potential. The result of this shift in the activation
and inactivation curves away from each other is that the
Naþ window current, represented by the area under the
2 curves, is minimized with lidocaine 0.36 mmol/L
(Figure 1, B).
Del Nido Cardioplegia Reduces the Incidence of
Spontaneous Activity During Cardioplegic Arrest,
and Delays Return of Activity During Reperfusion
To determine the relative ability of del Nido cardioplegia
to protect aged hearts, we studied senescent rats using our
working heart model of arrest with blood cardioplegia.
Sixteen of 20 hearts (80%) met the predetermined
functional criteria for inclusion in the study. Eight hearts
were arrested with standard cardioplegia and 8 were
arrested with del Nido cardioplegia. Cardiac temperature
was 21C  1C in each group after induction and
essentially was unchanged immediately before reperfusion
(20C  1C in each group).
Spontaneous electromechanical activity was observed
during the arrest period in 7 of 8 hearts in the standard
cardioplegia group (Figure 2). This was in the form of
occasional wide complex beats seen on the electrocardio-
gram (Figure 2, A) with accompanying mechanical activity.
In contrast, spontaneous activity was seen in only 1 of 8
hearts arrested with del Nido cardioplegia (Figure 2, B;
P ¼ .01).
After the start of reperfusion, all hearts had spontaneous
return of rhythm. However, the time to return of the first
heartbeat was twice as long in the del Nido group when
compared with the standard cardioplegia group (Figure 2,
C and D; 67  6 vs 32  5 s; P ¼ .0007). All hearts had
occasional extra systoles or short runs of bigeminy during
the reperfusion period. Four hearts in the standard
cardioplegia group and 1 heart in the del Nido group
(P ¼ not specified [NS]) had short runs of sustained
tachyarrhythmia that resolved spontaneously. One heart in
the del Nido group had a short period of asystole, which
was not seen in any of the hearts protected with standard
cardioplegia.
Use of del Nido Cardioplegia Results in Less
Myocardial Damage and Lower Coronary Vascular
Resistance During Reperfusion
To assess the impact of del Nido cardioplegia on
cardiomyocyte damage after arrest and reperfusion, we
assayed troponin I in the coronary effluent. Troponin levels
were approximately 70% less in hearts protected with del
Nido cardioplegia when compared with standard
cardioplegia (0.24  0.05 vs 0.89  0.23 ng/mL;
P¼ .02). We examined coronary vascular resistance during
the retrograde perfusion phase of reperfusion and found thatery c October 2013
FIGURE 1. Analysis of lidocaine impact on Naþ channel activation and inactivation kinetics. A, Activation (dashed line) and inactivation (solid line)
curves were generated in the presence and absence (control) of lidocaine 0.36 mmol/L as found in del Nido cardioplegia. Lidocaine shifts the activation
curve to the right and the inactivation curve to the left. B, Magnified view of the area highlighted in panel A. The area under the intersection of the control
activation and inactivation curves (solid arrow) represents the Naþ window current. This is minimized in the presence of lidocaine (open arrow).
Govindapillai et al Evolving Technology/Basic Scienceit was approximately 50% less in hearts arrested with
del Nido cardioplegia (0.75  0.05 vs 1.43  0.31 mm
Hg $ min $ mL1 $ g1; P ¼ .0497). This was caused by
an increase in resistance over baseline in the standard
cardioplegia group, which was not seen in the del Nido
cardioplegia group (D coronary vascular resistance 0.68 
0.22 vs0.05 0.04mmHg $min $mL1 $ g1;P¼.007).FIGURE 2. Analysis of spontaneous activity during cardioplegic arrest and
spontaneous ECG activity (upper panel), and Ao pressure fluctuation (lower pan
the percentage of hearts showing spontaneous activity during arrest with either s
start of reperfusion in hearts arrested with standard (upper panel) and del Nido
return of the first heart beat after reperfusion in hearts arrested with standard an
group). Ao, Aortic; ECG, electrocardiogram.
The Journal of Thoracic and CaDel Nido Cardioplegia Is Associated With Superior
Functional Recovery After Cardioplegic Arrest
To evaluate the impact of del Nido cardioplegia on
functional recovery, the hearts were switched into working
mode for 60 minutes after the 20-minute reperfusion period,
and hemodynamic parameters were examined at fixed
filling pressure (20 cm H2O, Table 2, Figure 3). All heartsreturn of first heart beat after reperfusion. A, Representative tracings of
el) in a heart arrested with standard cardioplegia. B, Bar graph representing
tandard or del Nido cardioplegia. C, Representative ECG tracings from the
cardioplegia (lower panel). D, Bar graph representing the average time to
d del Nido cardioplegia. Bars represent the mean  SEM (n ¼ 8 hearts per
rdiovascular Surgery c Volume 146, Number 4 943
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TABLE 2. Hemodynamic parameters measured during working heart mode
After reperfusion (min)
Parameter Baseline 5 10 15 30 45 60
Heart rate (bpm)
Standard 224  6 197  16 200  16 200  16 204  19 198  21 198  22
del Nido 219  6 228  8 231  9 235  6 233  9 233  11 229  12
P NS NS NS NS NS NS NS
Systolic pressure (mm Hg)
Standard 133  5 99  6 99  6 99  7 93  9 98  9 97  8
del Nido 138  4 128  4 127  5 128  4 127  4 125  5 123  4
P .5 .0006 .0008 .0006 .0001 .0011 .0018
Rate pressure product (3102 mm Hg $ min1)
Standard 30  1 20  2 20  2 20  2 19  3 20  3 20  3
del Nido 30  1 29  1 29  1 30  1 29  1 29  1 28  1
P .8 .0005 .0006 .0002 .0002 .0006 .0017
Cardiac output (mL $ min1 $ g1)
Standard 181  18 85  23 87  23 88  24 86  24 92  23 86  22
del Nido 196  9 177  14 180  16 181  15 177  14 174  13 173  14
P .6 .0007 .0006 .0007 .0009 .0017 .0008
Stroke volume (3102 mL $ g1)
Standard 81  7 40  10 41  10 41  10 40  10 43  10 40  10
del Nido 90  4 78  6 78  6 77  5 76  5 75  5 76  4
P .4 .0009 .0009 .0013 .0016 .0026 .0008
Coronary flow (mL $ min1 $ g1)
Standard 97  5 61  9 60  9 61  7 60  11 65  11 61  12
del Nido 103  7 101  6 101  6 101  6 101  6 99  6 101  9
P .6 .0009 .0008 .001 .0007 .0014 .0003
Mixed linear model analysis was not significant so post hoc comparisons were not performed (n¼ 8 per group up to the 30-minute time point, and n¼ 7 for the 45- and 60-minute
time points). NS, Not significant.
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each group in which air was entrained near the end of the
studies and therefore did not contribute data for the
final 2 time points. Hemodynamic parameters were not
significantly different during baseline working heart mode
in hearts arrested with either standard or del Nido
cardioplegia (Table 2, Figure 3). After reperfusion, hearts
protected with del Nido cardioplegia had higher peak
systolic pressure, left ventricular developed pressure, and
rate pressure product (Table 2, Figure 3). Cardiac output
was higher throughout the working heart period in hearts
arrested with del Nido cardioplegia as was stroke volume
and stroke work (Table 2, Figure 3).
Myocardial Edema Is Not Affected by Cardioplegia
Strategy
To assess the potential impact of cardioplegia strategy on
the development of myocardial edema, we examined the
water content in the ventricular myocardium at the end of
each study. The amount of myocardial water was similar
in each group (0.94  0.05 vs 0.92  0.02 g for standard
and del Nido cardioplegia, respectively;P¼NS). Similarly,
the ratio of water to dry weight of the ventricular
myocardium was not different (5.1  0.1 vs 4.9  0.1 for
standard and del Nido cardioplegia, respectively; P ¼ NS).944 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
Aged myocardium behaves differently than mature
myocardium during ischemia and is not as well protected
by some cardioplegia solutions.23,24 This may be one
reason why older patients undergoing cardiac surgery
have impaired recovery of ventricular function and lower
survival when compared with younger adult patients.1,2
The mechanism responsible for the intolerance to
ischemia appears to be related to accelerated
accumulation of intracellular Ca2þ.5-8 Strategies to limit
the accumulation of intracellular Ca2þ in aged hearts
improve the recovery of ventricular function after
ischemia.7,8 In previous studies,15 we observed that del
Nido cardioplegia, developed for the protection of
immature myocardium, potentially has beneficial effects
in cardiomyocytes from aged rats. The results of our current
study comparing a del Nido cardioplegia strategy with a
standard multidose 4:1 blood cardioplegia strategy suggest
that those benefits translate into reduced myocardial
damage and improved functional recovery in the whole
aged heart. The rats used for these isolated heart studies
were 23 to 24 months of age. Survival to this age in this
strain of rats is approximately 50%,25 which corresponds
to a human age of older than 70 years (World Health
Organization mortality statistics, 2013).ery c October 2013
FIGURE 3. Analysis of cardiac function before and after arrest and reperfusion. A, Representative tracings of aortic pressure (upper panels) and aortic flow
(lower panels) recorded in working heart mode. Baseline and postreperfusion tracings are shown from hearts arrested with standard (left panels) and del
Nido cardioplegia (right panels). B, Graph showing left ventricular developed pressure measured during working heart mode before (baseline) and at several
time points after 60 minutes of cardioplegic arrest and 20 minutes of reperfusion for the standard and del Nido cardioplegia groups. C, Graph showing
stroke work indexed to dry heart weight measured during working heart mode before and after cardioplegic arrest. Data points represent the
mean  SEM (n ¼ 8 per group up to the 30-minute time point and 7 per group for the 45- and 60-minute time points). *P  .001.
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common additive but the mechanism of benefit is not clearly
understood. Possibilities include coronary vasodilation to
improve cardioplegia delivery, prevention of reperfusion
arrhythmias, and reduction of Naþ influx via the window
current during arrest. During cardioplegic arrest, membrane
potential stabilizes at a relatively depolarized level at which
a small tonic inward Naþ current is active. This window
current is related to a small proportion of the voltage gated
Naþ channels that are available, open, and in the active
state.18-20 This is one potential drawback of depolarizing
cardioplegic arrest because Naþ influx is thought to be the
prime driver of Ca2þ overload.16,17 With a view to potential
optimization of the del Nido cardioplegia formulation, we
confirmed that lidocaine shifts the activation and
inactivation curves for Naþ channels in a way that
minimizes the potential for Naþ window current. This may
represent an important mechanism of benefit with del Nido
cardioplegia, and the lidocaine concentration in the current
formulation appears sufficient.
Analogous to the observations in our previous isolated
cardiomyocyte study,15 we found a reduction in sponta-
neous activity in hearts arrested with del Nido cardioplegia.The Journal of Thoracic and CaThis may be related to Naþ channel blockade with
lidocaine, but del Nido cardioplegia also contains slightly
more potassium and magnesium than our standard
cardioplegia, resulting in more pronounced membrane
depolarization9 that also may contribute to more effective
arrest. Reduced spontaneous activity during the ischemic
period should limit the development of intracellular
acidosis, which drives the Naþ, and subsequently Ca2þ,
influx that contributes to ischemia-reperfusion injury.
The time to the return of the first heartbeat was twice as
long with del Nido cardioplegia. This corresponds with
what we observed anecdotally in our clinical practice
when we switched from standard to del Nido cardioplegia
for our pediatric patients. This may represent a residual
effect of lidocaine but it is not clear if the delayed
resumption of rhythm plays any role in the benefit seen
with del Nido cardioplegia. It is possible that a period of
persistent inactivity during early reperfusion may improve
myocardial recovery in a manner similar to that seen with
the use of warm terminal cardioplegia.26
During ischemia and reperfusion, the late or persistent
inward Naþ current is increased,27,28 which can
predispose to early after potentials and arrhythmia.27 Thisrdiovascular Surgery c Volume 146, Number 4 945
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including lidocaine.28 In our study we saw no episodes of
ventricular fibrillation and only a few runs of tachycardia
that were short and self-limiting. We did not see a
significant reduction with del Nido cardioplegia, but we
cannot exclude the possibility that this might become
apparent in a larger study.
Coronary resistance during reperfusion was increased in
the standard cardioplegia group but not in the del Nido
cardioplegia group. This also may be related to the presence
of lidocaine in del Nido cardioplegia, which can promote
coronary arteriolar vasodilation.29 However, there are alter-
native explanations including the possibility of increased
microvascular obstruction related to hypothermia-induced
sludging,30 with the higher hematocrit level in the 4:1
standard cardioplegia.
In the adult, blood cardioplegia appears to offer superior
myocardial protection when compared with crystalloid
cardioplegia.31,32 However, the optimal dilution of the
cardioplegia solution is the subject of ongoing debate.
Although the benefits of blood cardioplegia are apparent
with minimal hematocrit level,32 it has been suggested
that concentrated blood cardioplegia improves recovery
by limiting the development of myocardial edema. We did
not see any difference in myocardial edema in this study
comparing del Nido (1:4 blood:crystalloid) and standard
cardioplegia (4:1). This may be because, despite different
dilutions, the estimated final oncotic pressure is similar in
both solutions (Table 1). Potential advantages of dilute
cardioplegia include reduced viscosity that may enhance
cardioplegia delivery,33 and reduced potential for
sludging and microvascular obstruction with hypother-
mia.30 Furthermore, all the Ca2þ in these cardioplegia
solutions comes from the blood component, so del Nido
has a lower Ca2þ concentration, which may be beneficial,
particularly in elderly hearts in which strategies to limit
Ca2þ influx can reduce ischemia-reperfusion injury.7,8
This study was a comparison of 2 cardioplegia strategies
that currently are used clinically,9-11 therefore del Nido
cardioplegia was administered as a single dose and
standard cardioplegia was delivered in multiple doses.
Evidence suggests that, in adults, multidose 4:1 blood
cardioplegia offers benefits over a single dose (reviewed
by Buckberg34), and is the strategy we currently use
clinically. In contrast, del Nido cardioplegia, which
typically is used as a single dose, or is re-dosed at long
intervals,9-11 compares favorably with multidose 4:1
cardioplegia.9 However, this is primarily in pediatric
patients in whom there is some evidence that re-dosing of
cardioplegia is detrimental.35 Therefore, the efficacy of
single-dose del Nido cardioplegia in children could be
related in part to the patient population rather than the
cardioplegia solution itself. Although some centers are
using del Nido cardioplegia in adults with single dosing946 The Journal of Thoracic and Cardiovascular Surgor long intervals between doses (60-120 min), it
remains to be determined if multiple dosing with del Nido
cardioplegia could provide additional benefits in mature
or aged hearts, and what the optimal re-administration
volume or interval would be. It should be kept in mind
that the administration of large volumes of del Nido
cardioplegia could result in increased systemic lidocaine
levels that may be a safety issue, particularly in patients
with impaired renal function.36
Limitations
The isolated heart model used in this study had several
limitations that must be considered when interpreting our
results. The isolated working heart preparation is viable
for only a limited time. Although it is possible to examine
cardiac function in the short term with this system, it is
not feasible to study hearts at more clinically relevant
time points (12 or 24 hours after reperfusion). The hearts
in this study were exposed to ambient room temperature
during the ischemic period, which would limit
re-warming compared with the clinical situation in which
systemic temperature is usually higher. Furthermore, the
isolated heart is not subject to noncoronary collateral flow
during the ischemic period, which might alter the efficacy
of the myocardial protection strategy by washing out the
cardioplegia and/or rewarming the myocardium. The
volume of autologous blood that we can collect from each
rat is limited. With 4:1 cardioplegia we are able to prepare
the induction dose plus 2 additional doses, which allows a
maximum 60-minute ischemic period if re-dosing occurs
every 20 minutes. If longer ischemic periods were possible,
benefits with del Nido cardioplegia might become less
apparent if the single-dose strategy becomes inadequate
with prolonged cross-clamp times. Although ischemia-
reperfusion injury is initiated primarily by Ca2þ overload,
other processes affect the development of myocardial injury
and evolution of functional recovery. For example, the
inflammatory system plays a role in the myocardial
damage that occurs early after reperfusion.37 Most of these
limitations need to be addressed in future studies in intact
animals.
CONCLUSIONS
We have shown that in isolated elderly hearts, a del Nido
cardioplegia strategy is associated with less spontaneous ac-
tivity during arrest, reducedmyocardial injury, and improved
functional recovery when compared with a standard
multidose 4:1 blood cardioplegia strategy. Additional studies
in awhole animalwill help todetermine if these results persist
in a more clinically relevant model, and justify clinical
studies in elderly patients undergoing cardiac surgery.
The authors wish to thank Richard Livingston for his technical
support and Karen Buth for statistical support.ery c October 2013
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Discussion
Dr J. William Gaynor (Philadelphia, Pa). I would like to
congratulate the authors on a very nice study and an excellent
presentation. It is always nice to discuss a paper that agrees with
your own beliefs.
We switched to del Nido at the Children’s Hospital in
Philadelphia several years ago, and we currently use it for all of
our patients from neonates to the young adults. We do not have
elderly patients very frequently at CHOP, but we do go into the
30- and 40-year-olds.
Our clinical experience mimics this completely. We usually use
a single dose. We see very little return of spontaneous activity, and
we have been very happy with the postoperative function.
That being said, when we retrospectively compared our early
outcomes, inotropic use, and everything to our previous crystalloid
cardioplegia, we could show no differences. So our anecdotal
experience is that we like it, it seems to facilitate the operation
by only having to give one dose, we do see less spontaneous
activity, but we cannot show a clinical difference.
Now, when you go to, as you mentioned in your future
directions, you move to elderly patients, you are going to be
dealing with myocardium that is ischemic or perhaps has beenrdiovascular Surgery c Volume 146, Number 4 947
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situation. So how do we move forward from this isolated heart
model of essentially elderly but normal myocardium to a clinical
trial where we can actually show a difference? Because I am afraid
it would take somany patients as to become not feasible to perform
that study. But that being said, we use del Nido, we are very happy
with it, and we do think it is a better myocardial protective strategy.
Thank you very much. I enjoyed your paper.
Mr Govindapillai. Thank you, Dr Gaynor. To try and answer
your question, I think that what needs to happen is we need to
look at a whole animal model first. There are some concerns in
terms of single dosing with del Nido with adult patients where pro-
cedures can be pretty long and so sometimes re-dosing can occur
over longer intervals than with our standard cardioplegia where948 The Journal of Thoracic and Cardiovascular Surgit is given in shorter intervals. But I think certainly the next step
would be to look at a whole animal model and see where the in-
flammatory system plays a role as well and that would be, to me,
the next logical step before you can move on to some sort of a clin-
ical trial, and hopefully we can see some differences there as well.
Dr Gaynor. We occasionally use multidose if we have a
particularly long cross-clamp or in the rare case where we do see
a return of activity, and it works very well if you give an additional
dose. But again, I think I agree with the findings, I think it is an
excellent protective strategy, I think it probably is applicable to a
wider range of patients, but I do think it is going to be very hard
to prove that in a clinical setting.
Thank you very much.
Mr Govindapillai. Thank you.ery c October 2013
